``Procaine Expert'' Joins Samaritan Pharmaceuticals Scientific Advisory Board.

Business Editors & Health/Medical Writers

BIOWIRE2K

LAS VEGAS--(BW HealthWire)--Oct. 2, 2001

Samaritan Pharmaceuticals, Inc. (OTCBB: SPHC), a developer of innovative treatments for high cortisol diseases, today announced Docteur Jean-Paul Tillement has graciously accepted a seat on Samaritan's Scientific Advisory Board. Dr. Tillement, an MD, Professor, and Head of Pharmacology at the Faculte de Medecine de Paris XII, France, leads a team of 20 scientists, that include medical doctors, pharmacists, and senior scientists. He is considered an expert in the pharmacology of the "family of drugs" that includes Procaine, the main ingredient in Samaritan's lead proprietary drug Anticort(TM), which recently finished FDA Phase l/ll clinical human trials. He is an accomplished academic, author, editor and his scientific work includes more than 540 publications. Dr. Tillement's main field of interest is in the field of Clinical Pharmacokinetics, Experimental and Clinical Nueropsychopharmacology and the Pharmacological Preservation of Mitochondria Functions (http://www.samaritanpharmaceuticals.com/tillement.html).

Upon his acceptance and in light of the recent "Attack on America," Professor Tillement stated, "I am pleased to accept your offer. I, personally, with all my colleagues, share your emotion and express our compassion toward the terrible situation you are facing. Consider us as citizens of the United States, engaged in the same war as you."

Dr. Vassili Papadopoulos, the Head of the Division of Hormone Research at Georgetown University Medical Center, stated, "It is a great honor to have Professor Tillement on the Scientific Advisory Board. His expertise and knowledge will be invaluable to our success." Samaritan's Scientific Advisory Board provides the company with scientific vision, product "drug candidate" guidance and industry contacts. Dr. Papadopoulos leads the Scientific Advisory Board.

Dr. Greeson, CEO of Samaritan, stated, "Dr. Tillement is what we consider one of the most knowledgeable experts on Procaine. Dr. Tillement's past scientific research on the `effectiveness of Procaine' will be invaluable in expanding Samaritan's strategic insight and drug development, especially since Anticort's primary ingredient is Procaine. Additionally, we hope Dr. Tillement's contributions will open exciting new opportunities in the fields of Alzheimer's, Breast Cancer and Cholesterol, already in pre-clinical trials at Samaritan Laboratories in accordance with our seven-year research collaboration with Georgetown University."

About Samaritan Pharmaceuticals:

Samaritan Pharmaceuticals is a biopharmaceutical company focused on the commercialization of affordable drug candidates and diagnostics to combat Alzheimer's, Cancer, Cholesterol and HIV for the benefit of mankind. Samaritan's drug, Anticort(TM), completed FDA Phase Ib/IIa Clinical human trials for HIV and plans to submit its final Phase l/ll "study report" to the FDA in early 2002. Samaritan established a seven-year research collaboration with Georgetown University, giving it a research arm, "Samaritan Laboratories," dedicated to developing new "high priority" drugs and diagnostics. The Company has an existing portfolio of three exclusively licensed and patented drug candidates and diagnostics. Samaritan's HIV drug Anticort(TM) is in late stage FDA clinical trials and has three drug candidates in pre-clinical trials, plus an Alzheimer's and Breast Cancer Diagnostic. Samaritan's financial partner is Fusion Capital with a placed equity line of $20 million, giving Samaritan cash, and more importantly, enough money to fund its Clinical trials. Register to receive future press releases automatically, or for more information visit: www.samaritanpharmaceuticals.com.

This release contains statements about the future that could differ from actual results. The statements are subject to risk and uncertainties, including but not limited to, the impact of competition, fluctuations in stock price and liquidity, fluctuating operating results and other risks as detailed in the company's filings with the SEC.